A Prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 1, 2010, Pages 11-18

  Arcangeli, Giorgio ^a   Saracino, Biancamaria ^a   Gomellini, Sara ^a   Petrongari, Maria Grazia ^a   Arcangeli, Stefano ^a   Sentinelli, Steno ^a   Marzi, Simona ^a   Landoni, Valeria ^a   Fowler, Jack ^b   Strigari, Lidia ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Conventional fractionation; Freedom from biochemical failure; High risk disease; Hypofractionated schedule; Prostate tumors; Toxicity

Indexed keywords

CONVENTIONAL FRACTIONATIONS; FREEDOM FROM BIOCHEMICAL FAILURES; HIGH-RISK DISEASE; HYPOFRACTIONATED SCHEDULE; PROSTATE TUMOR;

DISEASES; DOSIMETRY; MULTIVARIANT ANALYSIS; RADIOTHERAPY; TOXICITY; TUMORS;

THREE DIMENSIONAL;

BICALUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; SEMINAL VESICLE; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRILES; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; SEMINAL VESICLES; TOSYL COMPOUNDS;

EID: 77953961599     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1691     Document Type: Article

References (23)

1. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M.D. Anderson Phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
2. S.T.H. Peeters, W.D. Heemsbergen, and P.C.M. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
3. J. Fowler, R. Chappel, and M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
4. D.J. Brenner, A.A. Martinez, and G.K. Edmundson Direct evidence that prostate tumors shows high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
5. S.G. Williams, J.M. Taylor, and N. Liu Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer Int J Radiat Oncol Biol Phys 68 2007 24 33
6. G.G. Steel Basic clinical radiobiology 2003 Arnold London
7. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer. Cleveland Clinic experience Int J Radiat Oncol Biol Phys 63 2007 1424 1430
8. G. Soete, S. Arcangeli, and G. De Meerleer Phase II study of a four week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity Radiother Oncol 80 2006 78 81
9. B.L. Madsen, R.A. His, and H.T. Pham Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.4 Gy in five fractions for localized disease: First clinical trial results Int J Radiat Oncol Biol Phys 67 2007 1099 1105
10. H. Lukka, C. Hayter, and J.A. Julian A randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
11. E.E. Yeoh, R.H. Holloway, and R.J. Fraser Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a Phase III randomized trial Int J Radiat Oncol Biol Phys 66 2006 1072 1083
12. S.J. Feigensberger, A.L. Hanlon, and E.M. Horwitz Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 62 2005 397 405
13. E.H. Huang, A. Pollack, and L. Levy Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 54 2002 1314 1321
14. C. Burman, G.J. Kutcher, and B. Emami Fitting of normal tissue tolerance data to analytic function Int J Radiat Oncol Biol Phys 21 1991 123 135
15. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
16. M.J. Barry, F.J. Fowler Jr., and M.P. O'Leary The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148 1992 1549 1557
17. J.J. Pavy, J. Denekamp, and J. Letschert Late effects toxicity scoring: The SOMA scale Int J Radiat Oncol Biol Phys 31 1995 1043 1049
18. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
19. G. Sanguineti, S. Agostinelli, and F. Foppiano Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma Br J Cancer 86 2002 1843 1847
20. L. Strigari, G. Arcangeli, S. Arcangeli, and M. Benassi Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1454 1460
21. M.J. Zelefski, Y. Yamada, and Z. Fuks Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival Int J Radiat Oncol Biol Phys 71 2008 1028 1033
22. S.M. Bentzen, and M.A. Ritter The α/β ratio for prostate cancer: What is it, really? Radiother Oncol 76 2005 1 3
23. D.L. Joon, M. Hasegawa, and C. Sikes Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation Int J Radiat Oncol Biol Phys 38 1997 1071 1077